S&N gains exclusive rights to Acticoat dressing in $21m buy
This article was originally published in Clinica
Executive Summary
Smith & Nephew’s advanced wound management subsidiary has gained full control of the Acticoat antimicrobial barrier dressings range after the firm purchased the product’s manufacturer Nucryst Pharmaceuticals. Previously, S&N exclusively licensed the product from Nucryst. As part of the acquisition, S&N will acquire Nucryst’s Fort Saskatchewan, Canada-based operations and intellectual property related to the dressing for $21m. The Acticoat dressing utilises Nucryst’s Silcryst nanocrystalline silver coating technology and offers bacterial reduction, fluid management and sustained release of silver ions. It has a non-adherent design. Nucryst ran into trouble earlier this year when it received a notice from the Nasdaq that it was not in compliance with the exchange’s rules after it had traded at below $1.00 per share for more than 30 days.